NanoDx inks deal with IBM, seeks EUA for COVID-19 test

Updated Jul 14, 2021
2020 02 13 23 04 0191 Lab Scientists 400

NanoDx announced that it has signed a licensing deal with IBM Research and will pursue an emergency use authorization (EUA) from the U.S. Food and Drug Administration for a rapid COVID-19 test.

Under the deal, NanoDx will get use of IBM's complementary metal oxide semiconductor (CMOS)-compatible nanoscale sensors to enhance and expand rapid testing for conditions such as sepsis, stroke, traumatic brain injury, and COVID-19.

In addition, the company is seeking an EUA for a point-of-care COVID-19 testing platform that can detect and quantify biomarkers from a small fluid specimen in less than two minutes.

Page 1 of 4
Next Page